Shop

Author at Microdose

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Culture

3 Nov 2021

Celebrity Psychedelic Update: Psilocybin Helped Lil Nas X Create Latest Album

Now we have rap/pop star Lil Nas X telling the world that psychedelic mushrooms helped in the creation of his latest album “Montero....

By Jason Najum

Don’t Miss

2 Nov 2021

News You Might Have Missed: November 2, 2021

Welcome to the News You Might Have Missed, a weekly roundup of news items to help you catch up and stay informed....

By Jason Najum

Industry

29 Oct 2021

Cybin Gets FDA Study Approval and Launches New Training Program

This week the company returned to our news feeds with two solid announcements....

By Jason Najum

Events

29 Oct 2021

Microdose Announces PsiloThera as Private Room Sponsor

It’s an honor for Microdose to announce PsiloThera as a Gold Sponsor of Wonderland: Miami 2021....

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Culture

26 Oct 2021

Dune Was Inspired by Author’s Love of Mushrooms

Published in the 1960s and arguably the most famous sci-fi book ever, there have been decades of fan theories around its potential psychedelic inspiration....

By Jason Najum

Don’t Miss

25 Oct 2021

News You Might Have Missed: Oct 25, 2021

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine industry news items to help you catch up and stay informed....

By Jason Najum

Industry

22 Oct 2021

Small Pharma On a Roll With Price Surge and Major Milestones

Small Pharma On a Role With Price Surge and Major Milestones...

By Jason Najum

Culture

21 Oct 2021

Celebrities Continue to Come Out for Psychedelics

Celebrities Continue to Come Out for Psychedelics...

By Jason Najum

Finance

20 Oct 2021

H.C. Wainwright Gives atai Life Sciences a Buy Rating and $40 Price Target

H....

By Jason Najum

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.